Learn More
504Background: P provides a progression-free and overall survival (PFS, OS) benefit in HER2-positive MBC, and is standard of care in the 1st line. Continuing H post-progression on 1st-line H improves(More)
Purpose To assess the efficacy and safety of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who(More)